pharma · Ulcerative colitis · central nervous system (CNS) lymphomas · RANI
Rani Therapeutics Holdings
Rani Therapeutics is a pharma organization headquartered in San Jose, USA. It trades on NYSE under ticker RANI. Primary therapeutic focus areas include Ulcerative colitis, central nervous system (CNS) lymphomas, Obesity.
San Jose, USA HQ
2012 Founded
99 Employees
Public company Type
RANI · NYSE Ticker
Company details
- Status
- Public
- HQ
- San Jose, USA
- Founded
- 2012
- Employees
- 99
- Programs
- 7
- Drugs
- 12
- Patents
- 148
GRT-1C101
Phase 1 · other · Ulcerative colitis
GRT-1C101 for Ulcerative colitis is a Phase 1 program (other) at Rani Therapeutics Holdings with 1 ClinicalTrials.gov record(s).
Internal code GRT-1C101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Rani Therapeutics Holdings
- Phase
- Phase 1
- Modality
- other
- Indication
- Ulcerative colitis
- Status
- active
- Trials
- 1